Eleni Aklillu

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: INFECTIOUS DISEASES. 2024;56(4):308-319

Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis.

Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
Article: INFECTIOUS DISEASES OF POVERTY. 2024;13(1):8

Reduced efficacy of single-dose albendazole against Ascaris lumbricoides, and Trichuris trichiura, and high reinfection rate after cure among school children in southern Ethiopia: a prospective cohort study.

Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
Article: TROPICAL MEDICINE AND HEALTH. 2023;51(1):72

Efficacy and safety of praziquantel treatment against Schistosoma mansoni infection among pre-school age children in southern Ethiopia.

Tadele T; Astatkie A; Tadesse BT; Makonnen E; Aklillu E; Abay SM
Article: CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY. 2023;12(12):1884-1896

Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania.

Fimbo AM; Mlugu EM; Kitabi EN; Kulwa GS; Iwodyah MA; Mnkugwe RH; Kunambi PP; Malishee A; Kamuhabwa AAR; Minzi OM; Aklillu E
Article: DRUG SAFETY. 2023;46(10):961-974

Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study.

Khaemba C; Barry A; Omondi WP; Kirui E; Oluka M; Parthasarathi G; Njenga SM; Guantai A; Aklillu E
Article: PATHOGENS. 2023;12(9):1170

Efficacy of Single-Dose Praziquantel for the Treatment of Schistosoma mansoni Infections among School Children in Rwanda.

Kabatende J; Ntirenganya L; Mugisha M; Barry A; Ruberanziza E; Bienvenu E; Bergman U; Aklillu E
Article: SCIENTIFIC REPORTS. 2023;13(1):11438

Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients.

Sileshi T; Telele NF; Burkley V; Makonnen E; Aklillu E
Article: PATHOGENS. 2023;12(7):858

Prevalence and Determinants of Schistosoma mansoni Infection among Pre-School Age Children in Southern Ethiopia.

Tadele T; Astatkie A; Abay SM; Tadesse BT; Makonnen E; Aklillu E
Article: CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY. 2023;12(6):783-794

Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.

Chala A; Kitabi EN; Ahmed JH; Tadesse BT; Chaka TE; Makonnen E; Aklillu E
Article: SCIENTIFIC REPORTS. 2023;13(1):1446

Effect of pharmacogenetic variations on praziquantel plasma concentration and safety outcomes among school children in Rwanda.

Barry A; Kabatende J; Telele NF; Mnkugwe RH; Mugisha M; Ntirenganya L; Bienvenu E; Aklillu E
Article: PHARMACEUTICALS. 2023;16(2):139

Efficacy of Single-Dose Albendazole for the Treatment of Soil-Transmitted Helminthic Infections among School Children in Rwanda-A Prospective Cohort Study.

Kabatende J; Barry A; Mugisha M; Ntirenganya L; Bergman U; Bienvenu E; Aklillu E
Article: FRONTIERS IN PHARMACOLOGY. 2023;14:968106

Efficacy and safety of praziquantel preventive chemotherapy in Schistosoma mansoni infected school children in Southern Ethiopia: A prospective cohort study.

Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
Article: ETHIOPIAN JOURNAL OF HEALTH DEVELOPMENT. 2023;37(1)

Methicillin Resistant Staphylococcus aureus contamination of Health care worker gowns and Uniforms: A cross-sectional Study from the biggest teaching hospital in Ethiopia

Desta K; Aklillu E; Gebrehiwot Y; Enquoselassie F; Cantillon D; Al-Hassan L; Price JR; Newport MJ; Davey G; Woldeamanuel Y
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(23):15168

Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio.

Mlugu EM; Minzi OM; Kamuhabwa AAR; Diczfalusy U; Aklillu E
Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2022;124 Suppl 1:S69-S74

Blue Skies research is essential for ending the Tuberculosis pandemic and advancing a personalized medicine approach for holistic management of Respiratory Tract infections.

Ntoumi F; Petersen E; Mwaba P; Aklillu E; Mfinanga S; Yeboah-Manu D; Maeurer M; Zumla A
Article: JOURNAL OF CLINICAL MEDICINE. 2022;11(21):6300

Safety Surveillance of Mass Praziquantel and Albendazole Co-Administration in School Children from Southern Ethiopia: An Active Cohort Event Monitoring.

Gebreyesus TD; Makonnen E; Tadele T; Gashaw H; Degefe W; Gerba H; Tadesse BT; Gurumurthy P; Aklillu E
Article: DRUG SAFETY. 2022;45(8):909-922

Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study.

Kabatende J; Barry A; Mugisha M; Ntirenganya L; Bergman U; Bienvenu E; Aklillu E
Article: JOURNAL OF PERSONALIZED MEDICINE. 2022;12(7):1087

CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study.

Tadesse WT; Mlugu EM; Shibeshi W; Degu WA; Engidawork E; Aklillu E
Article: SCIENTIFIC REPORTS. 2022;12(1):9698

Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity.

Petros Z; Habtewold A; Makonnen E; Aklillu E
Article: PHARMACEUTICALS. 2022;15(5):594

Safety and Tolerability of Ivermectin and Albendazole Mass Drug Administration in Lymphatic Filariasis Endemic Communities of Tanzania: A Cohort Event Monitoring Study.

Fimbo AM; Minzi OM; Mmbando BP; Gurumurthy P; Kamuhabwa AAR; Aklillu E
Article: INFECTION AND DRUG RESISTANCE. 2022;15:6839-6852

Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis.

Sidamo T; Rao PS; Aklillu E; Shibeshi W; Park Y; Cho Y-S; Shin J-G; Heysell SK; Mpagama SG; Engidawork E
Article: INFECTION AND DRUG RESISTANCE. 2022;15:3135-3147

High Levels of Methicillin-Resistant Staphylococcus aureus Carriage Among Healthcare Workers at a Teaching Hospital in Addis Ababa Ethiopia: First Evidence Using mecA Detection.

Desta K; Aklillu E; Gebrehiwot Y; Enquselassie F; Cantillon D; Al-Hassan L; Price JR; Newport MJ; Davey G; Woldeamanuel Y
Article: PLOS ONE. 2022;17(1):e0262604

Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.

Tadesse WT; Adankie BT; Shibeshi W; Amogne W; Aklillu E; Engidawork E
Article: JOURNAL OF PERSONALIZED MEDICINE. 2021;11(12):1303

Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study.

Chala A; Tadesse BT; Chaka TE; Mukonzo J; Kitabi EN; Tadesse S; Pohanka A; Makonnen E; Aklillu E
Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2021;113 Suppl 1(Suppl 1):S7-S12

Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts.

Chakaya J; Khan M; Ntoumi F; Aklillu E; Fatima R; Mwaba P; Kapata N; Mfinanga S; Hasnain SE; Katoto PDMC; Bulabula ANH; Sam-Agudu NA; Nachega JB; Tiberi S; McHugh TD; Abubakar I; Zumla A
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021;110(6):1478-1489

Effectiveness of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaqunine Against Malaria in Pregnancy in Tanzania: A Randomized Controlled Trial.

Mlugu EM; Minzi O; Kamuhabwa AAR; Aklillu E
Article: SCIENTIFIC REPORTS. 2021;11(1):17955

Optimal single sampling time-point for monitoring of praziquantel exposure in children.

Mnkugwe RH; Ngaimisi Kitabi E; Kinung'hi S; Kamuhabwa AAR; Minzi OM; Aklillu E
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2021;178(16):3294-3308

Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.

Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Burhenne J; Diczfalusy U
Article: PHARMACEUTICALS. 2021;14(5):400

Effect of Dihydroartemisinin-Piperaquine on the Pharmacokinetics of Praziquantel for Treatment of Schistosoma mansoni Infection.

Minzi OM; Mnkugwe RH; Ngaimisi E; Kinung'hi S; Hansson A; Pohanka A; Kamuhabwa A; Aklillu E
Article: PHARMACEUTICALS. 2021;14(3):264

Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study.

Khaemba C; Barry A; Omondi WP; Bota K; Matendechero S; Wandera C; Siyoi F; Kirui E; Oluka M; Nambwa P; Gurumurthy P; Njenga SM; Guantai A; Aklillu E
Article: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2021;18(4):1941

Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania.

Barry A; Olsson S; Khaemba C; Kabatende J; Dires T; Fimbo A; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; van Puijenbroek E; Bergman U; Nkayamba A; Mugisha M; Gurumurthy P; Aklillu E
Article: BMC MEDICAL EDUCATION. 2021;21(1):36

Understanding the key processes of excellence as a prerequisite to establishing academic centres of excellence in Africa.

Fekadu A; Oppenheim C; Manyazewal T; Nislow C; Woldeamanuel Y; Hailu A; Belete A; Wondimagegn D; Hanlon C; Gebremariam T; Collins A; Larson CJ; Gebreyes W; Aklilu E; Muula AS; Mugus S; Caffrey CR; Giday M; Yimer G; Davey G; Medhin G; Makonnen E
Article: FRONTIERS IN PHARMACOLOGY. 2021;12:712084

Effect of Pharmacogenetics Variations on Praziquantel Plasma Concentrations and Schistosomiasis Treatment Outcomes Among Infected School-Aged Children in Tanzania.

Mnkugwe RH; Minzi O; Kinung'hi S; Kamuhabwa A; Aklillu E
Article: INFECTION AND DRUG RESISTANCE. 2021;14:5473-5489

Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study.

Sidamo T; Shibeshi W; Yimer G; Aklillu E; Engidawork E
Article: CLINICAL PHARMACOLOGY: ADVANCES AND APPLICATIONS. 2021;13:1-12

The Impact of First-Line Anti-Tubercular Drugs' Pharmacokinetics on Treatment Outcome: A Systematic Review.

Sileshi T; Tadesse E; Makonnen E; Aklillu E
Article: PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2021;40(1):60-65

Predictors of Virologic Failure Among a Cohort of HIV-infected Children in Southern Ethiopia.

Tadesse BT; Foster BA; Latour E; Lim JY; Jerene D; Ruff A; Aklillu E
Article: PATHOGENS. 2020;9(12):1076

Prevalence, Intensity, and Correlates of Soil-Transmitted Helminth Infections among School Children after a Decade of Preventive Chemotherapy in Western Rwanda.

Kabatende J; Mugisha M; Ntirenganya L; Barry A; Ruberanziza E; Mbonigaba JB; Bergman U; Bienvenu E; Aklillu E
Article: PATHOGENS. 2020;9(11):E920-920

Prevalence, Intensity, and Correlates of Schistosomiasis and Soil-Transmitted Helminth Infections after Five Rounds of Preventive Chemotherapy among School Children in Southern Ethiopia.

Gebreyesus TD; Tadele T; Mekete K; Barry A; Gashaw H; Degefe W; Tadesse BT; Gerba H; Gurumurthy P; Makonnen E; Aklillu E
Article: PLOS NEGLECTED TROPICAL DISEASES. 2020;14(9):e0008619

Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial.

Mnkugwe RH; Minzi O; Kinung'hi S; Kamuhabwa A; Aklillu E
Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(5):E1550-1550

Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania.

Fimbo AM; Minzi OMS; Mmbando BP; Barry A; Nkayamba AF; Mwamwitwa KW; Malishee A; Seth MD; Makunde WH; Gurumurthy P; Lusingu JPA; Kamuhabwa AAR; Aklillu E
Article: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. 2020;17(9):E3123-3123

Prevalence and Correlates of Asymptomatic Malaria and Anemia on First Antenatal Care Visit among Pregnant Women in Southeast, Tanzania.

Mlugu EM; Minzi O; Kamuhabwa AAR; Aklillu E
Article: MALARIA JOURNAL. 2020;19(1):160

Effect of sulfadoxine-pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania.

Mikomangwa WP; Minzi O; Mutagonda R; Baraka V; Mlugu EM; Aklillu E; Kamuhabwa AAR
Article: DRUG SAFETY. 2020;43(4):339-350

Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.

Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
Article: PATHOGENS. 2020;9(3):E207-207

Effectiveness of Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria and Adverse Birth Outcomes in Pregnant Women.

Mlugu EM; Minzi O; Asghar M; Färnert A; Kamuhabwa AAR; Aklillu E
Article: EXPERT REVIEW OF CARDIOVASCULAR THERAPY. 2020;18(3):165-173

Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya.

Nyamu DG; Guantai AN; Osanjo GO; Godman B; Aklillu E
Article: MALARIA JOURNAL. 2020;19(1):66

Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania.

Kilonzi M; Minzi O; Mutagonda R; Baraka V; Sasi P; Aklillu E; Kamuhabwa A
Article: TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. 2020;114(2):107-114

Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients.

Mukonzo JK; Kengo A; Kutesa B; Nanzigu S; Pohanka A; McHugh TD; Zumla A; Aklillu E
Article: WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY. 2020;21(1):29-52

Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism.

Djordjevic N; Radmanovic B; Cukic J; Baskic D; Djukic-Dejanovic S; Milovanovic D; Aklillu E
Article: FRONTIERS IN PHARMACOLOGY. 2020;11:26

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations.

Mugusi S; Habtewold A; Ngaimisi E; Amogne W; Yimer G; Minzi O; Makonnen E; Sudfeld C; Burhenne J; Aklillu E
Article: FRONTIERS IN PHARMACOLOGY. 2020;11:406

Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients.

Ahmed JH; Makonnen E; Bisaso RK; Mukonzo JK; Fotoohi A; Aseffa A; Howe R; Hassan M; Aklillu E
Article: PLOS ONE. 2020;15(2):e0228770

Prevalence and correlates of intestinal schistosomiasis infection among school-aged children in North-Western Tanzania.

Mnkugwe RH; Minzi OS; Kinung'hi SM; Kamuhabwa AA; Aklillu E
Article: PATHOGENS. 2019;9(1):E28-28

Efficacy and Safety of Praziquantel for Treatment of Schistosoma mansoni Infection among School Children in Tanzania.

Mnkugwe RH; Minzi OS; Kinung'hi SM; Kamuhabwa AA; Aklillu E
Article: DRUG METABOLISM AND DISPOSITION. 2019;47(12):1415-1424

Pregnancy and CYP3A5 Genotype Affect Day 7 Plasma Lumefantrine Concentrations.

Mutagonda RF; Minzi OMS; Massawe SN; Asghar M; Färnert A; Kamuhabwa AAR; Aklillu E
Journal article: PHARMACOGENETICS AND GENOMICS. 2019;29(9):224

PharmGKB summary: very important pharmacogene information for CYP1A2: Erratum.
Article: PATHOGENS. 2019;8(4):E161-161

Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study.

Tadesse BT; Chala A; Mukonzo J; Chaka TE; Tadesse S; Makonnen E; Brumme ZL; Brumme CJ; Aklillu E
Article: VIRUSES-BASEL. 2019;11(9):E877-877

Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia.

Tadesse BT; Tsai O; Chala A; Chaka TE; Eromo T; Lapointe HR; Baraki B; Shahid A; Tadesse S; Makonnen E; Brumme ZL; Aklillu E; Brumme CJ
Article: CANCERS. 2019;11(9):E1353-1353

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients.

Ahmed JH; Makonnen E; Fotoohi A; Aseffa A; Howe R; Aklillu E
Article: BMC PREGNANCY AND CHILDBIRTH. 2019;19(1):236

Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region.

Mikomangwa WP; Oms M; Aklillu E; Kamuhabwa AAR
Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2019;83:98-101

Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals.

Mukonzo J; Aklillu E; Marconi V; Schinazi RF
Article: MALARIA JOURNAL. 2019;18(1):133

Comparison of malaria treatment outcome of generic and innovator's anti-malarial drugs containing artemether-lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children.

Kilonzi M; Minzi O; Mutagonda R; Sasi P; Kamuhabwa A; Aklillu E
Article: JOURNAL OF CLINICAL MEDICINE. 2019;8(4):E430-430

HIV and cART-Associated Dyslipidemia Among HIV-Infected Children.

Tadesse BT; Foster BA; Chala A; Chaka TE; Bizuayehu T; Ayalew F; H/Meskel G; Tadesse S; Jerene D; Makonnen E; Aklillu E
Article: HIV MEDICINE. 2019;20(2):147-156

Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study.

Tadesse BT; Foster BA; Kabeta A; Ayalew F; H/Meskel G; Jerene D; Makonnen E; Aklillu E
Article: NUTRIENTS. 2019;11(2):E289-289

Vitamin D Status and Association of VDR Genetic Polymorphism to Risk of Breast Cancer in Ethiopia.

Ahmed JH; Makonnen E; Fotoohi A; Yimer G; Seifu D; Assefa M; Tigeneh W; Aseffa A; Howe R; Aklillu E
Article: FRONTIERS IN PHARMACOLOGY. 2019;10:481

CYP2J2∗7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients.

Ahmed JH; Makonnen E; Yimer G; Seifu D; Bekele A; Assefa M; Aseffa A; Howe R; Fotoohi A; Hassan M; Aklillu E
Article: AAS OPEN RESEARCH. 2019;2:19

African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa.

Dandara C; Masimirembwa C; Haffani YZ; Ogutu B; Mabuka J; Aklillu E; Bolaji O; H3Africa
Journal article: 2018

Rifampicin-Efavirenz Drug Interactions and Cytochrome P450 3A (CYP3A) Enzyme Induction in Patients with Tuberculosis and HIV Co-Infection - A Prospective Cohort Study

Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Nylé n H; Bertilsson L; Burhenne JUR; Diczfalusy U
Article: SCIENTIFIC REPORTS. 2018;8(1):16316

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.

Kitabi EN; Minzi OMS; Mugusi S; Sasi P; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(11):1405-1415

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
Article: SCIENTIFIC REPORTS. 2018;8(1):12726

Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations.

Bedada W; de Andrés F; Engidawork E; Hussein J; LLerena A; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(7):903-911

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.

Aklillu E; Carrillo JA; Makonnen E; Bertilsson L; Djordjevic N
Article: VIRUSES-BASEL. 2018;10(2):E60-60

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.

Tadesse BT; Kinloch NN; Baraki B; Lapointe HR; Cobarrubias KD; Brockman MA; Brumme CJ; Foster BA; Jerene D; Makonnen E; Aklillu E; Brumme ZL
Journal article: PROCEEDINGS FOR ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY. 2018;WCP2018(0):sy48-sy42

African Pharmacogenomics Research Consortium: Focus on HIV, Tuberculosis and Malaria treatment

Aklillu E
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2017;61(8):e00207-e00217

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.

Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
Article: MALARIA JOURNAL. 2017;16(1):267

Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women.

Mutagonda RF; Kamuhabwa AAR; Minzi OMS; Massawe SN; Asghar M; Homann MV; Färnert A; Aklillu E
Article: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2017;21(4):207-216

Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.

Petros Z; Lee MTM; Takahashi A; Zhang Y; Yimer G; Habtewold A; Schuppe-Koistinen I; Mushiroda T; Makonnen E; Kubo M; Aklillu E
Journal article: BMJ GLOBAL HEALTH. 2017;2(Suppl 2):a39

CYP2B6 GENOTYPE BASED EFAVIRENZ DOSE RECOMMENDATIONS DURING RIFAMPICIN-BASED ANTITUBERCULOSIS CO-TREATMENT FOR A SUB-SAHARAN AFRICA POPULATION

Mukonzo J; Kuteesa R; Ogwal-Okeng J; Gustafsson LL; Owen J; Aklillu E
Journal article: BMJ GLOBAL HEALTH. 2017;2(Suppl 2):a11

PREVALENCE AND RISK FACTORS FOR EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT-ASSOCIATED SEVERE VITAMIN D DEFICIENCY: A PROSPECTIVE COHORT STUDY

Nylén H; Habtewold A; Makonnen E; Yimer G; Burhenne J; Diczfalusy U; Aklillu E
Article: FRONTIERS IN PHARMACOLOGY. 2017;8:90

HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians.

Petros Z; Kishikawa J; Makonnen E; Yimer G; Habtewold A; Aklillu E
Article: LIVER INTERNATIONAL. 2017;37(1):132-140

Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.

Mikus M; Drobin K; Gry M; Bachmann J; Lindberg J; Yimer G; Aklillu E; Makonnen E; Aderaye G; Roach J; Fier I; Kampf C; Göpfert J; Perazzo H; Poynard T; Stephens C; Andrade RJ; Lucena MI; Arber N; Uhlén M; Watkins PB; Schwenk JM; Nilsson P; Schuppe-Koistinen I
Journal article: BMJ GLOBAL HEALTH. 2017;2(Suppl 2):a1-a72

Abstracts of the Eighth EDCTP Forum, 6-9 November 2016.
Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2016;56(12):1538-1549

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.

Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
Article: BMC GENOMICS. 2016;17(1):755

Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.

Petros Z; Lee M-TM; Takahashi A; Zhang Y; Yimer G; Habtewold A; Amogne W; Aderaye G; Schuppe-Koistinen I; Mushiroda T; Makonnen E; Kubo M; Aklillu E
Article: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2016;20(9):538-545

SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine.

Aklillu E; Habtewold A; Ngaimisi E; Yimer G; Mugusi S; Amogne W; Reuter T; Meid A; Hoffmann MM; Weiss J
Article: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2016;20(9):496-497

Conference Report: First Pharmacogenetics and Precision Medicine Conference in Africa (April 7-9, 2016, Cape Town, South Africa).

Dandara C; Suarez-Kurtz G; Aklillu E
Article: MEDICINE. 2016;95(34):e4631

Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.

Nylén H; Habtewold A; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
Article: MALARIA JOURNAL. 2016;15(1):278

Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women.

Mutagonda RF; Kamuhabwa AAR; Minzi OMS; Massawe SN; Maganda BA; Aklillu E
Article: PHARMACOGENOMICS. 2016;17(6):603-613

CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.

Mukonzo JK; Bisaso RK; Ogwal-Okeng J; Gustafsson LL; Owen JS; Aklillu E
Article: PHARMACOGENOMICS JOURNAL. 2016;16(1):88-95

CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.

Maganda BA; Minzi OMS; Ngaimisi E; Kamuhabwa AAR; Aklillu E
Article: PLOS ONE. 2016;11(8):e0161685

High Gastrointestinal Colonization Rate with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia.

Desta K; Woldeamanuel Y; Azazh A; Mohammod H; Desalegn D; Shimelis D; Gulilat D; Lamisso B; Makonnen E; Worku A; Mannerqvist K; Struwe J; Aspevall O; Aklillu E
Article: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2015;19(12):777-781

P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 Activity in Swedish, But Not in Korean Healthy Subjects.

Hatta FHM; Aklillu E
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2015;35(6):694-699

The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans.

Bedada W; de Andrés F; Engidawork E; Pohanka A; Beck O; Bertilsson L; Llerena A; Aklillu E
Article: PHARMACOLOGY RESEARCH & PERSPECTIVES. 2015;3(6):e00192

miRNA-27b levels are associated with CYP3A activity in vitro and in vivo.

Ekström L; Skilving I; Ovesjö M-L; Aklillu E; Nylén H; Rane A; Diczfalusy U; Björkhem-Bergman L
Article: DRUG METABOLISM AND DISPOSITION. 2015;43(8):1226-1235

The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.

Chaudhry AS; Prasad B; Shirasaka Y; Fohner A; Finkelstein D; Fan Y; Wang S; Wu G; Aklillu E; Sim SC; Thummel KE; Schuetz EG
Article: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2015;19(6):346-353

Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex.

Hatta FHM; Lundblad M; Ramsjo M; Kang J-H; Roh H-K; Bertilsson L; Eliasson E; Aklillu E
Article: MALARIA JOURNAL. 2015;14:179

The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.

Maganda BA; Ngaimisi E; Kamuhabwa AAR; Aklillu E; Minzi OMS
Article: PLOS ONE. 2015;10(5):e0122587

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
Article: PHARMACOGENOMICS. 2015;16(10):1047-1064

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.

Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2014;69(12):3311-3319

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.

Ngaimisi E; Minzi O; Mugusi S; Sasi P; Riedel K-D; Suda A; Ueda N; Bakari M; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E; Diczfalusy U
Article: PHARMACOGENETICS AND GENOMICS. 2014;24(8):409-425

PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

McDonagh EM; Boukouvala S; Aklillu E; Hein DW; Altman RB; Klein TE
Article: PHARMACOGENOMICS. 2014;15(11):1423-1435

CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.

Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
Article: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2014;18(7):446-453

High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.

Aklillu E; Djordjevic N; Carrillo JA; Makonnen E; Bertilsson L; Ingelman-Sundberg M
Article: JOURNAL OF APPLIED GENETICS. 2014;55(2):163-171

The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.

Sominsky S; Korostishevsky M; Kurnik D; Aklillu E; Cohen Y; Ken-Dror G; Loebstein R; Halkin H; Gak E
Article: LIVER INTERNATIONAL. 2014;34(3):367-378

Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts.

Thulin P; Nordahl G; Gry M; Yimer G; Aklillu E; Makonnen E; Aderaye G; Lindquist L; Mattsson CM; Ekblom B; Antoine DJ; Park BK; Linder S; Harrill AH; Watkins PB; Glinghammar B; Schuppe-Koistinen I
Article: PLOS ONE. 2014;9(1):e86919

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.

Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
Article: PLOS ONE. 2014;9(4):e94271

Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.

Yimer G; Gry M; Amogne W; Makonnen E; Habtewold A; Petros Z; Aderaye G; Schuppe-Koistinen I; Lindquist L; Aklillu E
Article: PHARMACOGENOMICS JOURNAL. 2013;13(6):484-489

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.

Habtewold A; Amogne W; Makonnen E; Yimer G; Nylén H; Riedel K-D; Aderaye G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
Article: BMC INFECTIOUS DISEASES. 2013;13:536

CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans.

Aklillu E; Odenthal-Hesse L; Bowdrey J; Habtewold A; Ngaimisi E; Yimer G; Amogne W; Mugusi S; Minzi O; Makonnen E; Janabi M; Mugusi F; Aderaye G; Hardwick R; Fu B; Viskaduraki M; Yang F; Hollox EJ
Article: BMC INFECTIOUS DISEASES. 2013;13:261

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.

Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
Article: ENVIRONMENTAL AND MOLECULAR MUTAGENESIS. 2013;54(2):124-132

Haplotypes in the 5'-untranslated region of the CYP1A2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism.

Gervasini G; Ghotbi R; Aklillu E; San Jose C; Cabanillas A; Kishikawa J; Benitez J; Carrillo JA
Article: DRUG METABOLISM AND PHARMACOKINETICS. 2013;28(2):93-97

Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans.

Djordjevic N; Carrillo JA; van den Broek MPJ; Kishikawa J; Roh H-K; Bertilsson L; Aklillu E
Article: PLOS ONE. 2013;8(11):e78165

Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa.

Machado LR; Bowdrey J; Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Yimer G; Amogne W; Mugusi S; Janabi M; Aderaye G; Mugusi F; Viskaduraki M; Aklillu E; Hollox EJ
Article: PLOS ONE. 2013;8(7):e67946

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.

Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel K-D; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
Article: PHARMACOGENOMICS JOURNAL. 2012;12(6):499-506

High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study.

Yimer G; Amogne W; Habtewold A; Makonnen E; Ueda N; Suda A; Worku A; Haefeli WE; Burhenne J; Aderaye G; Lindquist L; Aklillu E
Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2012;52(10):1527-1534

Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans.

Djordjevic N; Carrillo JA; Roh H-K; Karlsson S; Ueda N; Bertilsson L; Aklillu E
Article: JOURNAL OF INFECTIOUS DISEASES. 2012;206(7):1012-1019

β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans.

Hardwick RJ; Amogne W; Mugusi S; Yimer G; Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Janabi M; Machado LR; Viskaduraki M; Mugusi F; Aderaye G; Lindquist L; Hollox EJ; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2012;68(7):1033-1042

Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.

Hatta FHM; Teh LK; Helldén A; Hellgren KE; Roh H-K; Salleh MZ; Aklillu E; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 2012;22(5):389-395

PharmGKB summary: caffeine pathway.

Thorn CF; Aklillu E; McDonagh EM; Klein TE; Altman RB
Article: ANTIVIRAL THERAPY. 2012;17(2):265-274

Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania.

Mugusi SF; Ngaimisi E; Janabi MY; Mugusi FM; Minzi OMS; Sasi PG; Bakari M; Lindquist L; Aklillu E; Sandstrom EG
Article: PHARMACOGENETICS AND GENOMICS. 2012;22(1):73-77

PharmGKB summary: very important pharmacogene information for CYP1A2.

Thorn CF; Aklillu E; Klein TE; Altman RB
Article: PLOS ONE. 2012;7(7):e40180

Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.

Mugusi S; Ngaimisi E; Janabi M; Minzi O; Bakari M; Riedel K-D; Burhenne J; Lindquist L; Mugusi F; Sandstrom E; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2011;67(11):1139-1145

Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.

Aklillu E; Mugusi S; Ngaimisi E; Hoffmann MM; König S; Ziesenitz V; Mikus G; Haefeli WE; Weiss J
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2011;66(10):2350-2361

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.

Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel K-D; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2011;90(3):406-413

Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.

Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel K-D; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
Journal article: CLINICAL PHARMACOKINETICS. 2011;50(9):624

Erratum to: HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects

Mukonzo JK; Nanzigu S; Rekić D; Waako P; Röshammar D; Ashto M; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Article: CLINICAL PHARMACOKINETICS. 2011;50(8):531-540

HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.

Mukonzo JK; Nanzigu S; Rekić D; Waako P; Röshammar D; Ashton M; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2011;51(7):994-1003

N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population.

Djordjevic N; Carrillo JA; Ueda N; Gervasini G; Fukasawa T; Suda A; Jankovic S; Aklillu E
Article: PHARMACOGENOMICS JOURNAL. 2011;11(2):130-137

Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.

Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E
Article: PLOS ONE. 2011;6(12):e27810

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

Yimer G; Ueda N; Habtewold A; Amogne W; Suda A; Riedel K-D; Burhenne J; Aderaye G; Lindquist L; Makonnen E; Aklillu E
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2010;88(5):676-684

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.

Ngaimisi E; Mugusi S; Minzi OM; Sasi P; Riedel K-D; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Burhenne J; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(9):871-877

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.

Ramsjö M; Aklillu E; Bohman L; Ingelman-Sundberg M; Roh H-K; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(7):697-703

Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.

Djordjevic N; Ghotbi R; Jankovic S; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(6):571-578

In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population.

Djordjevic N; Carrillo JA; Gervasini G; Jankovic S; Aklillu E
Article: THERAPEUTIC DRUG MONITORING. 2010;32(3):346-352

Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans.

Mukonzo JK; Waako P; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(5):465-474

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.

Ghotbi R; Mannheimer B; Aklillu E; Suda A; Bertilsson L; Eliasson E; Osby U
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2009;68(5):690-699

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.

Mukonzo JK; Röshammar D; Waako P; Andersson M; Fukasawa T; Milani L; Svensson JO; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Article: PHARMACOGENOMICS JOURNAL. 2009;9(3):208-217

Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers.

Ghotbi R; Gomez A; Milani L; Tybring G; Syvänen A-C; Bertilsson L; Ingelman-Sundberg M; Aklillu E
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19(5):363-370

MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs.

Hilli J; Heikkinen T; Rontu R; Lehtimäki T; Kishida I; Aklillu E; Bertilsson L; Vahlberg T; Laine K
Article: PHARMACOGENETICS AND GENOMICS. 2009;19(4):267-275

Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression.

Aklillu E; Karlsson S; Zachrisson OO; Ozdemir V; Agren H
Article: HUMAN MUTATION. 2008;29(9):1147-1153

Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme.

Chavarria-Soley G; Sticht H; Aklillu E; Ingelman-Sundberg M; Pasutto F; Reis A; Rautenstrauss B
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2008;64(4):381-385

Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes.

Djordjevic N; Ghotbi R; Bertilsson L; Jankovic S; Aklillu E
Article: PLOS ONE. 2008;3(3):e1809

Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients.

Yimer G; Aderaye G; Amogne W; Makonnen E; Aklillu E; Lindquist L; Yamuah L; Feleke B; Aseffa A
Article: PHARMACOGENETICS AND GENOMICS. 2008;18(3):201-208

4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.

Diczfalusy U; Miura J; Roh H-K; Mirghani RA; Sayi J; Larsson H; Bodin KG; Allqvist A; Jande M; Kim J-W; Aklillu E; Gustafsson LL; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 2007;17(11):989-993

CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.

Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
Article: NEUROPSYCHOPHARMACOLOGY. 2007;32(10):2143-2151

Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression.

Kishida I; Aklillu E; Kawanishi C; Bertilsson L; Agren H
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2007;81(5):708-712

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.

Josephson F; Allqvist A; Janabi M; Sayi J; Aklillu E; Jande M; Mahindi M; Burhenne J; Bottiger Y; Gustafsson LL; Haefeli WE; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2007;63(6):537-546

Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Ghotbi R; Christensen M; Roh H-K; Ingelman-Sundberg M; Aklillu E; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 2006;16(9):637-645

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.

Mirghani RA; Sayi J; Aklillu E; Allqvist A; Jande M; Wennerholm A; Eriksen J; Herben VMM; Jones BC; Gustafsson LL; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 2006;16(5):359-367

Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype.

Jiang Z; Dragin N; Jorge-Nebert LF; Martin MV; Guengerich FP; Aklillu E; Ingelman-Sundberg M; Hammons GJ; Lyn-Cook BD; Kadlubar FF; Saldana SN; Sorter M; Vinks AA; Nassr N; von Richter O; Jin L; Nebert DW
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;79(1):103-113

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Sim SC; Risinger C; Dahl M-L; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
Article: CANCER RESEARCH. 2005;65(12):5105-5111

Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene.

Aklillu E; Øvrebø S; Botnen IV; Otter C; Ingelman-Sundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(7):533-536

Xanthine oxidase activity is influenced by environmental factors in Ethiopians.

Aklillu E; Carrillo JA; Makonnen E; Bertilsson L; Ingelman-Sundberg M
Article: MOLECULAR PHARMACOLOGY. 2003;64(3):659-669

Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.

Aklillu E; Carrillo JA; Makonnen E; Hellman K; Pitarque M; Bertilsson L; Ingelman-Sundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2002;58(8):555-558

Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations.

Yasar U; Aklillu E; Canaparo R; Sandberg M; Sayi J; Roh H-K; Wennerholm A
Journal article: DRUG NEWS AND PERSPECTIVES. 2002;15(8):528-534

Recent Progress in Drug Metabolism Research.

Aklillu E; Hidestrand M; Ingelman-Sundberg M; Malmebo S; Westlind A
Article: PHARMACOGENETICS AND GENOMICS. 2002;12(5):375-383

Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden.

Aklillu E; Herrlin K; Gustafsson LL; Bertilsson L; Ingelman-Sundberg M
Article: MOLECULAR PHARMACOLOGY. 2002;61(3):586-594

Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population.

Aklillu E; Oscarson M; Hidestrand M; Leidvik B; Otter C; Ingelman-Sundberg M
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2001;52(4):447-450

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(6):521-526

S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.

Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1996;278(1):441-446

Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.

Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
Visa fler

Alla övriga publikationer

Review: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2024;141S:107002

Screening for latent tuberculosis in migrants-status quo and future challenges.

Petersen E; Al-Abri S; Al-Jardani A; Memish ZA; Aklillu E; Ntoumi F; Mwaba P; Wejse C; Zumla A; Al-Yaquobi F
Conference publication: 2023;:a37.3-a3a38

PA-118 Safety monitoring during mass drug administration: adverse events following the use of Ivermectin, Diethylcarbamazine and Albendazole for the control of lymphatic filariasis in Kenya

Khaemba C; Barry A; Omondi W; Kirui E; Mandale M; Oluka M; Gurumurthy P; Njenga S; Guantai A; Aklillu E
Conference publication: 2023;:a35.2-a3a35

PA-96 Surveillance of hematological and biochemical changes following mass Ivermectin and Albendazole administration for the control of lymphatic filariasis in endemic communities of Tanzania

Fimbo AM; Minzi O; Aklillu E
Conference publication: 2023;:a32.1-a3a32

PA-74 Efficacy of single dose albendazole for the treatment of soil-transmitted infections among school children in Southern Ethiopia

Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
Editorial comment: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2023;131:180-182

End of the Bedaquiline patent - a crucial development for moving forward affordable drugs, diagnostics, and vaccines for infectious diseases in low- and middle-income countries.

Petersen E; Hui DS; Nachega JB; Ntoumi F; Goletti D; Aklillu E; Sharma A; Nyirenda T; Yeboah-Manu D; Satta G; da Costa C; Azhar EI; Bockarie M; Al-Abri S; McHugh TD; Rodriguez-Morales AJ; Varghese GM; Zumla A
Editorial comment: LANCET RESPIRATORY MEDICINE. 2022;10(6):533-536

Optimising tuberculosis care for refugees affected by armed conflicts.

Castro KG; Ditiu L; Sahu S; Ntoumi F; Tiberi S; O'Kane CM; Akkerman O; Manika K; Mwaba P; Davies Forsman L; Petersen E; Aklillu E; Azhar EI; Cirillo DM; Migliori G-B; Abbara A; Zumla A
Editorial comment: LANCET INFECTIOUS DISEASES. 2022;22(4):442-444

World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis.

Ntoumi F; Nachega JB; Aklillu E; Chakaya J; Felker I; Amanullah F; Yeboah-Manu D; Castro KG; Zumla A
Review: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2022;15:561-571

Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.

Sileshi T; Mekonen G; Makonnen E; Aklillu E
Editorial comment: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2022;114:268-272

Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts.

Petersen E; Ntoumi F; Hui DS; Abubakar A; Kramer LD; Obiero C; Tambyah PA; Blumberg L; Yapi R; Al-Abri S; Pinto TDCA; Yeboah-Manu D; Haider N; Asogun D; Velavan TP; Kapata N; Bates M; Ansumana R; Montaldo C; Mucheleng'anga L; Tembo J; Mwaba P; Himwaze CM; Hamid MMA; Mfinanga S; Mboera L; Raj T; Aklillu E; Veas F; Edwards S; Kaleebu P; McHugh TD; Chakaya J; Nyirenda T; Bockarie M; Nyasulu PS; Wejse C; Muyembe-Tamfum J-J; Azhar EI; Maeurer M; Nachega JB; Kock R; Ippolito G; Zumla A
Review: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2021;17(9):1125-1138

The impact of catha edulis (vahl) forssk. ex endl. (celestraceae) (khat) on pharmacokinetics of clinically used drugs.

Aklillu E; Engidawork E
Preprint: RESEARCH SQUARE. 2020

Effect of Sulfadoxine-Pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania

Mikomangwa WP; Minzi O; Mutagonda R; Baraka V; Mlugu E; Aklillu E; Kamuhabwa AAR
Preprint: RESEARCH SQUARE. 2019

Effect of Sulfadoxine-Pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania

Mikomangwa WP; Minzi O; Mutagonda R; Baraka V; Mlugu EM; Aklillu E; Kamuhabwa AAR
Letter: HIV MEDICINE. 2019;20(7):e13-e14

Rebuttal: Response to the comments by Buck et al. on our published article: Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study; HIV Medicine (2019), 20, 147-156.

Tadesse BT; Foster A; Aklillu E
Review: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2019;85(3):467-475

Conference report: pharmacogenomics in special populations at WCP2018.

Suarez-Kurtz G; Aklillu E; Saito Y; Somogyi AA
Conference publication: TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE. 2019;113:S270-S271

HIV AND CART ASSOCIATED DYSLIPIDEMIA AMONG HIV INFECTED CHILDREN

Tadesse BT; Foster BA; Bizuayehu T; Ayalew F; Meskel GH; Jerene D; Makonnen E; Aklillu E
Conference publication: HIV MEDICINE. 2019;20:285

Rifampicin pharmacokinetics and pharmacogenetics in Ugandan patients with multi-drug resistant tuberculosis

Mukonzo JK; Kengo A; Kutesa R; Nanzigu S; Pohanka A; Hugh M; Zumla A; Aklillu E
Preprint: AAS OPEN RES. 2019

African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa

Dandara C; Masimirembwa C; Haffani Y; Ogutu B; Mabuka J; Aklillu E; Bolaji O; H3Africa
Conference publication: DRUG SAFETY. 2018;41(11):1107-1108

The Proforma Project Presentation

Aklillu E
Conference publication: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2018;21:122

Efavirenz plasma exposure and immunologic outcome during anti-tuberculosis co-therapy: role of ethnicity and pharmacogenetic variations

Mugusi S; Amogne W; Habtewold A; Ngaimisi E; Yimer G; Minzi O; Makonnene E; Mugusi F; Sudfeld C; Janabi M; Burhenne J; Aklillu E
Review: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2017;21(3):123-131

Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.

Petros Z; Makonnen E; Aklillu E
Conference publication: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2017;101(S1):S66-S67

POPULATION PHARMACOKINETICS OF A MAJOR METABOLITE OF EFAVIRENZ, 8-HYDROXY-EFAVIRENZ, IN PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS

Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen J
Editorial comment: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2016;20(9):493-495

Precision Medicine 2.0: The Rise of Glocal Innovation, Superconnectors, and Design Thinking.

Dandara C; Endrenyi L; Kolker E; Hekim N; Steuten LMG; Güngör K; Aklillu E; Özdemir V
Letter: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2016;20(4):259-262

An Open Letter in Support of Transformative Biotechnology and Social Innovation: SANKO University Innovation Summit in Medicine and Integrative Biology, Gaziantep, Turkey, May 5-7, 2016.

Saygılı Eİ; Abou-Zeid AH; Akkın SM; Aklillu E; Barlas İÖ; Borda-Rodriguez A; Boschele FA; Çetin Z; Coşkun E; Coşkun Y; Dağlı G; Dai TU; Dandara C; Dereli T; Elbeyli L; Endrenyi L; Eyigün CP; Georgakilas A; Günbulut B; Güngör K; Güzelbey A; Hekim C; Huzair F; Kimyon S; Karakaş Ü; Lin B; LLerena A; Masimirembwa C; McNally R; Mete A; Sancar P; Srivastava S; Steuten LM; Tanrıöver O; Tyfield D; Töre Vİ; Vuruşkan D; Wang W; Warnich L; Wonkam A; Yıldırım YZ; Yılmaz İ; Sınav A; Hekim N
Editorial comment: CLINICAL INFECTIOUS DISEASES. 2015;61(9):1432-1438

Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates.

Zumla A; Maeurer M; Host-Directed Therapies Network (HDT-NET) Consorti
Editorial comment: NATURE REVIEWS DRUG DISCOVERY. 2015;14(8):511-512

Towards host-directed therapies for tuberculosis.

Zumla A; Maeurer M; Host-Directed Therapies Network; Chakaya J; Hoelscher M; Ntoumi F; Rustomjee R; Vilaplana C; Yeboah-Manu D; Rasolof V; Munderi P; Singh N; Aklillu E; Padayatchi N; Macete E; Kapata N; Mulenga M; Kibiki G; Mfinanga S; Nyirenda T; Maboko L; Garcia-Basteiro A; Rakotosamimanana N; Bates M; Mwaba P; Reither K; Gagneux S; Edwards S; Mfinanga E; Abdulla S; Cardona P-J; Russell JBW; Gant V; Noursadeghi M; Elkington P; Bonnet M; Menendez C; Dieye TN; Diarra B; Maiga A; Aseffa A; Parida S; Wejse C; Petersen E; Kaleebu P; Oliver M; Craig G; Corrah T; Tientcheu L; Antonio M; Rao M; McHugh TD; Sheikh A; Ippolito G; Ramjee G; Kaufmann SHE; Churchyard G; Steyn A; Grobusch M; Sanne I; Martinson N; Madansein R; Wilkinson RJ; Mayosi B; Schito M; Wallis RS
Editorial comment: LANCET INFECTIOUS DISEASES. 2015;15(1):11-13

Genesis of EDCTP2.

Zumla A; Makanga M; Nyirenda T; Beattie P; Olesen OF; Breugelmans JG; Aklillu E; Corrah T; Mgone C
Conference publication: JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS. 2015;42:S25

Pharmacogenetic-Based Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Efavirenz on Adult Ethiopian HIV and TB/HIV Patients

Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Owen JS
Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2014;115:232-233

TB-HIV CO-INFECTION AND CONCOMITANT ANTI-TB THERAPY AND HAART INCREASES THE RISK FOR DRUG INDUCED LIVER INJURY: A PROSPECTIVE FOUR-ARM COHORT STUDY

Ali G; Gry M; Amogne W; Makonnen E; Habtewold A; Petros Z; Aderaye G; Schuppe-Koistinen I; Lindquist L; Aklillu E
Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2014;115:166

INVESTIGATING THE DETERMINANTS OF EFAVIRENZ PHARMACOKINETIC PARAMETERS AFTER LONG TERM TREATMENT WITH AND WITHOUT RIFAMPICIN AMONG TANZANIAN HIV/TB AND HIV PATIENTS

Ngaimisi E; Minzi O; Mugusi S; Janabi M; Sasi P; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2014;115:73

IS THERE A NEED FOR EFAVIRENZ DOSAGE ADJUSTMENT DURING CONCOMITANT RIFAMPICIN BASED ANTITUBERCULOSIS THERAPY? FINDINGS FROM THE HIV-TB PHARMAGENE STUDY

Habtewold A; Makonnen E; Amogne W; Ali G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Conference publication: TOXICOLOGY LETTERS. 2012;211:S48

Qualification of new biomarkers for drug-induced liver injury in a human cohort

Thulin P; Gry M; Nordahl G; Yimer G; Linder S; Aklillu E; Glinghammar B; Schuppe-Koistinen I
Conference publication: TOXICOLOGY LETTERS. 2012;211:S9

Pharmacogenomic biomarkers for drug induced liver injury

Aklillu E
Conference publication: TROPICAL MEDICINE & INTERNATIONAL HEALTH. 2012;17:22-23

Optimization of TB and HIV co-treatment: pharmacokinetic and pharmacogenetic aspects of interaction between rifampicin and efavirenz (EFV)

Aklillu E
Conference publication: IMMUNOLOGY. 2011;135:141

β-Defensin genomic copy number is associated with HIV viral load and immune reconstitution in sub-Saharan Africans

Hardwick R; Amogne W; Mugusi S; Yimer G; Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Janabi M; Machado L; Mugusi F; Aderaye G; Lindquist L; Hollox E; Aklillu E
Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2011;109:23

XANTHINE OXIDASE AND N-ACETYLTRANSFERASE-2 ENZYME ACTIVITIES IN SWEDES AND KOREANS: AN INTER-ETHNIC COMPARISON

Djordjevic N; Carrillo JA; Gervasini G; Ueda N; Roh H-K; Aklillu E
Corrigendum: CLINICAL PHARMACOKINETICS. 2011;50(9):624

HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects (vol 50, pg 531, 2011)

Mukonzo JK; Nanzigu S; Rekic D; Waako P; Roeshammar D; Ashton M; Ogwal-Okeng J; Gustafsson LL; Aklillu E
Conference publication: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2009;68:7

THE AUTO INDUCTION OF EFAVIRENZ METABOLISM AND THE RESULTING EFFECT ON THE EFAVIRENZ STEADY STATE LEVELS IN TANZANIAN PATIENTS

Ngaimisi E; Mugusi S; Minzi O; Sasi P; Janabi M; Mugusi F; Bakari M; Aris E; Sandstrom E; Bertilsson L; Burhenne J; Aklillu E
Conference publication: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2009;68:6

STEADY STATE EFAVIRENZ PHARMACOKINETICS PROFILE AMONG HIV PATIENTS IN ETHIOPIA

Eyakem A; Amogne W; Yimer G; Makonnen E; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2009;105:81

N-ACETYLTRANSFERASE-2 (NAT2) GENE POLYMORPHISMS AND ENZYME ACTIVITY IN SERBS: UNPRECEDENTED HIGH PREVALENCE OF RAPID ACETYLATORS IN A WHITE POPULATION

Djordjevic N; Carrillo JA; Gervasini G; Jankovic S; Aklillu E
Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2009;105:21-22

CORRELATION OF CYP2A6 ENZYME ACTIVITY WITH GENOTYPE AND CIGARETTE SMOKING IN SERBS

Djordjevic N; Carrillo JA; Gervasini G; Jankovic S; Aklillu E
Letter: BLOOD. 2008;111(7):3903-3904

VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals.

Aklillu E; Leong C; Loebstein R; Halkin H; Gak E
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S328

Monoamine metabolites level in CSF are related to the 5-HTT gene polymorphism in treatment-resistant depression

Kishida I; Aklillu E; Kawanishi C; Bertilsson L; Agren H
Meeting abstract: TOXICOLOGY LETTERS. 2006;164:S92

Anti-tubercular drug-induced hepatotoxicity in HIV-positive and negative patients

Yimer G; Aseffa A; Aklillu E; Makonnen E; Amogne W; Bobosha K; Golka K; Rane A; Lindquist L; Aderaye G
Meeting abstract: TOXICOLOGY LETTERS. 2006;164:S98

Distribution and concordance of phenotypically and genotypically determined acetylation status on patients taking anti-tuberculosis drugs in Ethiopia

Yimer G; Golka K; Aseffa A; Aklillu E; Makonnen E; Amogne W; Bobosha K; Rane A; LindquiSt L; Aderaye G
Meeting abstract: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 2006;21(4):A33

CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo

Miura J; Aklillu E; Allqvist A; Gustafsson LL; Jande M; Mirghani RA; Sayi J; Wennerholm A; Widen J; Bertilsson L
Review: EXPERT OPINION ON PHARMACOTHERAPY. 2006;7(2):119-133

Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.

Ozdemir V; Aklillu E; Mee S; Bertilsson L; Albers LJ; Graham JE; Caligiuri M; Lohr JB; Reist C
Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2005;59(5):413

Monoamine metabolites in CSF are related to serotonin transporter promoter gene polymorphism in treatment-resistant major depression.

Kishida I; Aklillu E; Bertilsson L; Ågren H; Kawanishi C
Conference publication: CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY. 2004;31(11):A220

Genetic polymorphisms of CYP1A2 and xanthine oxidase in ethiopians affecting expression: Characterization of novel CYP1A2 haplotypes

Aklillu E; Carrillo JA; Mekonen E; Bertilsson L; Ingelman-Sundberg M
Visa fler

Forskningsbidrag

Building resilient research ethics, Diagnostics and medicines regulatory capacity during routine and public health emergency periods (BREEDIME)

Global Health EDCTP3 Joint Undertaking

1 June 2024 - 31 May 2026
Safety and efficacy of Dolutegravir and EFV400 for pregnant and breast feeding women: a randomized non-inferiority clinical trial (PREGART)

EDCTP

1 June 2018 - 31 December 2025
Pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa

European & Developing Countries Clinical Trials Partnership

1 March 2018 - 31 August 2024
Randomized clinical trial to identify optimal pediatric efavirenz dosage to treat HIV infected infant and children in Africa

Swedish Research Council

1 January 2016 - 31 December 2019
Healthcare associated infections, antimicrobial use and resistance in Ethiopia: an intervention study for rational antimicrobials use, prevention of resistance and limit their spread.

Swedish Research Council

1 January 2012 - 31 December 2014
Vårdrelaterade infektioner, antimikrobiella användningen och multiresistenta bakterier-en interventionsstudie för rationell antibiotika användning, förebyggande av infektion utbrott

Swedish Research Council

1 January 2012 - 31 December 2014
Metabolism, transport and effects of drugs - Pharmacogenetic, interethnic, and clinical aspects

Swedish Research Council

1 January 2010 - 31 December 2012

Anställningar

Professor, Global folkhälsa, Karolinska Institutet, 2023-
Professor, Laboratoriemedicin, Karolinska Institutet, 2020-2023
Forskare, Laboratoriemedicin, Karolinska Institutet, 2011-2020
Forskare, Laboratoriemedicin, Karolinska Institutet, 2003-2006
Doktorand, Institutet för miljömedicin, Karolinska Institutet, 2002-2003

Examina och utbildning

Docent, Farmakologi, Karolinska Institutet, 2009
MEDICINE DOKTORSEXAMEN, Institutet för miljömedicin, Karolinska Institutet, 2003

Uppdrag

Forskargruppsledare, Global Health Pharmacology and Therapeutics (GH-Pharma) – Eleni Aklillu's research group, Department of Global Public Health, Karolinska Institutet, 2023-

Handledare

Joseph Kabatende, Pharmacovigilance of mass drug administration for the control of schistosomiasis and soil transmitted helminths in Rwanda., https://openarchive.ki.se/xmlui/handle/10616/48601

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Uppdrag

Handledare

Nyheter från KI

Kalenderhändelser från KI